← Back to Search

18F-FDG PET Scan for Cardiovascular Disease

Phase < 1
Recruiting
Led By Guobao Wang, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the procedure
Awards & highlights

Study Summary

This trial will use a single-tracer PET scan to measure both blood flow and glucose metabolism in the body. Researchers believe it can be done using only 18F-FDG.

Who is the study for?
This trial is for adults over 18 who can consent and follow the study schedule. Healthy volunteers must have no cardiovascular or metabolic diseases, while patients with such conditions can join. Exclusions include high blood glucose, weight over 240 kg, pregnancy, recent PET scans in other studies, prisoners, and those unable to consent.Check my eligibility
What is being tested?
The trial aims to develop a PET imaging method using a single tracer (18F-FDG) to assess both blood flow and glucose metabolism simultaneously. This could potentially streamline the process of diagnosing various conditions related to heart and metabolic health.See study design
What are the potential side effects?
Potential side effects may include reactions from the injection site due to tracer administration or discomfort from lying still during scanning. Anxiety or claustrophobia might occur due to enclosed space of the scanner.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood Flow
Secondary outcome measures
Metabolism change when using Butanol
Metabolism change when using FDG

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental: PET/CT scansExperimental Treatment2 Interventions
Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-FDG
2010
Completed Phase 2
~660

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
911 Previous Clinical Trials
4,709,459 Total Patients Enrolled
National Institute for Biomedical Imaging and Bioengineering (NIBIB)NIH
89 Previous Clinical Trials
19,691 Total Patients Enrolled
Guobao Wang, PhDPrincipal InvestigatorUniversity of California, Davis
2 Previous Clinical Trials
24 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants being enrolled in this medical experiment presently?

"Affirmative. As indicated by information on clinicaltrials.gov, this medical research venture is actively recruiting participants. It was first posted on September 1st, 2023 and the most current update was made seven days later. This trial requires sixty individuals to be recruited from a single location."

Answered by AI

How many individuals are undergoing this research?

"Affirmative. Clinicaltrials.gov has the data to support that this research project, which commenced on September 1st 2023, is recruiting patients right now. Specifically, 60 people are needed from one medical centre for this trial."

Answered by AI
~40 spots leftby Aug 2028